GlassScriptPhysician profile
Brian S Torrey
NPI 1356442578
$14,185.50
in general payments reported to CMS, 2019-2025
67 companies · $2,063 in 2025
The $2,063 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,416 · 2020: $1,614 · 2021: $1,787 · 2022: $2,082 · 2023: $2,393 · 2024: $1,830 · 2025: $2,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,212 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,211.68 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,647.67 | 2019-2025 | |
| Abbvie INC. | $1,475.11 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,305.91 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $955.13 | 2019-2025 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $867.43 | 2019-2024 | Trintellix |
| Lilly USA, LLC | $813.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $743.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.00 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $493.16 | 2019-2024 | Spravato |
| Glaxosmithkline, LLC. | $439.28 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $418.00 | 2019-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $406.42 | 2019-2024 | Ajovy |
| Merck Sharp & Dohme LLC | $396.07 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.59 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Biohaven Pharmaceuticals, INC. | $221.71 | 2021 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Torrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.